Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KMT2D mutation
i
Other names:
KMT2D, Lysine Methyltransferase 2D, Histone-Lysine N-Methyltransferase 2D, Myeloid/Lymphoid Or Mixed-Lineage Leukemia 2, Lysine (K)-Specific Methyltransferase 2D, Trinucleotide Repeat Containing 21, Lysine N-Methyltransferase 2D, ALL1-Related Protein, MLL2, MLL4, ALR, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein, Histone-Lysine N-Methyltransferase MLL2, Truncated Lysine Methyltransferase 2D, Kabuki Mental Retardation Syndrome, Kabuki Make-Up Syndrome, CAGL114, KABUK1, TNRC21, AAD10
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
8085
Related biomarkers:
Expression
Mutation
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
KMT2D mutation
Squamous Cell Carcinoma of Head and Neck
KMT2D mutation
Squamous Cell Carcinoma of Head and Neck
durvalumab + tremelimumab
Sensitive: B - Late Trials
durvalumab + tremelimumab
Sensitive
:
B
durvalumab + tremelimumab
Sensitive: B - Late Trials
durvalumab + tremelimumab
Sensitive
:
B
KMT2D mutation
Follicular Lymphoma
KMT2D mutation
Follicular Lymphoma
Resistant: C3 – Early Trials
Resistant
:
C3
Resistant: C3 – Early Trials
Resistant
:
C3
KMT2D mutation
Diffuse Large B Cell Lymphoma
KMT2D mutation
Diffuse Large B Cell Lymphoma
chidamide
Resistant: C3 – Early Trials
chidamide
Resistant
:
C3
chidamide
Resistant: C3 – Early Trials
chidamide
Resistant
:
C3
KMT2D mutation
Diffuse Large B Cell Lymphoma
KMT2D mutation
Diffuse Large B Cell Lymphoma
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
KMT2D mutation
Marginal Zone Lymphoma
KMT2D mutation
Marginal Zone Lymphoma
ibrutinib
Resistant: C3 – Early Trials
ibrutinib
Resistant
:
C3
ibrutinib
Resistant: C3 – Early Trials
ibrutinib
Resistant
:
C3
KMT2D mutation
Colorectal Cancer
KMT2D mutation
Colorectal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
KMT2D mutation
Non Small Cell Lung Cancer
KMT2D mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
KMT2D mutation
Cervical Cancer
KMT2D mutation
Cervical Cancer
anlotinib + sintilimab
Sensitive: C3 – Early Trials
anlotinib + sintilimab
Sensitive
:
C3
anlotinib + sintilimab
Sensitive: C3 – Early Trials
anlotinib + sintilimab
Sensitive
:
C3
KMT2D mutation
Triple Negative Breast Cancer
KMT2D mutation
Triple Negative Breast Cancer
cyclophosphamide + epirubicin
Resistant: C3 – Early Trials
cyclophosphamide + epirubicin
Resistant
:
C3
cyclophosphamide + epirubicin
Resistant: C3 – Early Trials
cyclophosphamide + epirubicin
Resistant
:
C3
KMT2D mutation
Non Small Cell Lung Cancer
KMT2D mutation
Non Small Cell Lung Cancer
PD1 inhibitor
Sensitive: C3 – Early Trials
PD1 inhibitor
Sensitive
:
C3
PD1 inhibitor
Sensitive: C3 – Early Trials
PD1 inhibitor
Sensitive
:
C3
KMT2D mutation
Marginal Zone Lymphoma
KMT2D mutation
Marginal Zone Lymphoma
zanubrutinib
Resistant: C3 – Early Trials
zanubrutinib
Resistant
:
C3
zanubrutinib
Resistant: C3 – Early Trials
zanubrutinib
Resistant
:
C3
KMT2D mutation
Chronic Lymphocytic Leukemia
KMT2D mutation
Chronic Lymphocytic Leukemia
decitabine
Sensitive: D – Preclinical
decitabine
Sensitive
:
D
decitabine
Sensitive: D – Preclinical
decitabine
Sensitive
:
D
KMT2D mutation
Chronic Lymphocytic Leukemia
KMT2D mutation
Chronic Lymphocytic Leukemia
chidamide
Sensitive: D – Preclinical
chidamide
Sensitive
:
D
chidamide
Sensitive: D – Preclinical
chidamide
Sensitive
:
D
KMT2D mutation
Chronic Lymphocytic Leukemia
KMT2D mutation
Chronic Lymphocytic Leukemia
ibrutinib + chidamide
Sensitive: D – Preclinical
ibrutinib + chidamide
Sensitive
:
D
ibrutinib + chidamide
Sensitive: D – Preclinical
ibrutinib + chidamide
Sensitive
:
D
KMT2D mutation
Chronic Lymphocytic Leukemia
KMT2D mutation
Chronic Lymphocytic Leukemia
ibrutinib + decitabine
Sensitive: D – Preclinical
ibrutinib + decitabine
Sensitive
:
D
ibrutinib + decitabine
Sensitive: D – Preclinical
ibrutinib + decitabine
Sensitive
:
D
KMT2D mutation
Lung Cancer
KMT2D mutation
Lung Cancer
afatinib + SHP099
Sensitive: D – Preclinical
afatinib + SHP099
Sensitive
:
D
afatinib + SHP099
Sensitive: D – Preclinical
afatinib + SHP099
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login